Interlaboratory-concordance of PD-L1 IHC for NSCLC

被引：0
|
作者：
Scheel, Andreas H.
Banfer, Gudrun
Baretton, Gustavo Bruno
Dietel, Manfred
Diezko, Rolf
Henkel, Thomas
Heukamp, Lukas C.
Jasani, Bharat
Johrens, Korinna
Kirchner, Thomas
Petersen, Iver
Reu, Simone
Schildhaus, Hans-Ulrich
Schirmacher, Peter
Tiemann, Markus
Warth, Arne
Weichert, Wilko
Wolf, Juergen
Ruschoff, Josef
Buettner, Reinhard
机构：
[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany
[2] Targos Mol Pathol GmbH, Kassel, Germany
[3] Univ Hosp Carl Gustav Carus, Dresden, Germany
[4] Charite, Inst Pathol, Berlin, Germany
[5] TARGOS Mol Pathol GmbH, Kassel, Germany
[6] Haematopathol Hamburg, Hamburg, Germany
[7] NEO New Oncol GmbH, Hamburg, Germany
[8] Charite, Inst Pathol, Campus Berlin Mitte, Berlin, Germany
[9] Univ Munich, Dept Pathol, Munich, Germany
[10] Univ Hosp Jena, Inst Pathol, Jena, Germany
[11] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany
[12] Univ Hosp Gottingen, Inst Pathol, Gottingen, Germany
[13] Heidelberg Univ, Patholog Inst, Heidelberg, Germany
[14] Universitatsklinikum Heidelberg, Dept Pathol, Translat Lung Res Ctr Heidelberg, Heidelberg, Germany
[15] Tech Univ Munich, Inst Pathol, Munich, Germany
[16] Univ Hosp Cologne, Lung Canc Grp Cologne, Ctr Integrated Oncol, Cologne, Germany
[17] Nordhessen & Targos Mol Pathol GmbH, Inst Pathol, Kassel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20508
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Niu, Mengke
    Yi, Ming
    Li, Ning
    Luo, Suxia
    Wu, Kongming
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [42] PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
    Hirsch, Fred R.
    McElhinny, Abigail
    Stanforth, Dave
    Ranger-Moore, James
    Jansson, Malinka
    Kulangara, Karina
    Richardson, William
    Towne, Penny
    Hanks, Debra
    Vennapusa, Bharathi
    Mistry, Amita
    Kalamegham, Rasika
    Averbuch, Steve
    Novotny, James
    Rubin, Eric
    Emancipator, Kenneth
    McCaffery, Ian
    Williams, J. Andrew
    Walker, Jill
    Longshore, John
    Tsao, Ming Sound
    Kerr, Keith M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 208 - 222
  • [43] Whole Body PD-1 and PD-L1 PET in Pts with NSCLC
    Niemeijer, A.
    Smit, E.
    Van Dongen, G.
    Windhorst, A. D.
    Huisman, M.
    Hendrikse, N.
    Bahce, I.
    Lueng, D.
    Smith, R.
    Hayes, W.
    Wilson, L.
    Bonacorsi, S.
    Donnelly, D.
    Morin, P.
    Poot, A.
    Vugts, D.
    Thunnissen, E.
    De Langen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1817 - S1817
  • [44] PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC
    Jorgensen, Jan Trost
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [45] Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases
    Batur, Sebnem
    Dulger, Onur
    Durak, Sermin
    Yumuk, Perran Fulden
    Caglar, Hale Basak
    Bozkurtlar, Emine
    Bozkurt, Suheyla
    Tastekin, Ebru
    Cicin, Irfan
    Ahiskali, Rengin
    Rzazade, Rashad
    Cakir, Asli
    Oz, Buge
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2020, 20 (03) : 329 - 335
  • [46] Ezrin regulates the progression of NSCLC by YAP and PD-L1
    Bu, Fan
    Zhang, Yeping
    Zhao, Ning
    Tian, Xiaoai
    Xu, Yirong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (07): : 2239 - 2249
  • [47] Ezrin regulates the progression of NSCLC by YAP and PD-L1
    Fan Bu
    Yeping Zhang
    Ning Zhao
    Xiaoai Tian
    Yirong Xu
    Clinical and Translational Oncology, 2023, 25 : 2239 - 2249
  • [48] Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC
    Bassanelli, Maria
    Sioletic, Stefano
    Martini, Maurizio
    Giacinti, Silvana
    Viterbo, Antonella
    Staddon, Anita
    Liberati, Fabrizio
    Ceribelli, Anna
    ANTICANCER RESEARCH, 2018, 38 (07) : 3789 - 3796
  • [49] The interaction of PD-L1, TMB, and genomic alterations in NSCLC
    Goldberg, Michael E.
    Gay, Laurie M.
    Fabrizio, David
    Frampton, Garrett M.
    Elvin, Julia A.
    Ross, Jeffrey S.
    Miller, Vincent A.
    Stephens, Philip J.
    Albacker, Lee A.
    CANCER RESEARCH, 2017, 77
  • [50] Clinicopathologic values of PD-L1 expression and polymorphism in NSCLC
    Kim, K. -H.
    VIRCHOWS ARCHIV, 2017, 471 : S110 - S111
12345